4.87
price up icon2.10%   0.10
after-market Handel nachbörslich: 4.87
loading
Schlusskurs vom Vortag:
$4.77
Offen:
$4.63
24-Stunden-Volumen:
500.91K
Relative Volume:
0.49
Marktkapitalisierung:
$362.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.87M
KGV:
-2.6906
EPS:
-1.81
Netto-Cashflow:
$-109.90M
1W Leistung:
-4.70%
1M Leistung:
-30.73%
6M Leistung:
-46.60%
1J Leistung:
-47.01%
1-Tages-Spanne:
Value
$4.625
$5.185
1-Wochen-Bereich:
Value
$4.59
$5.38
52-Wochen-Spanne:
Value
$3.8951
$14.67

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name
Firmenname
Oric Pharmaceuticals Inc
Name
Telefon
(650) 388-5600
Name
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
115
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
ORIC's Discussions on Twitter

Vergleichen Sie ORIC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ORIC
Oric Pharmaceuticals Inc
4.87 362.95M 0 -119.87M -109.90M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-31 Eingeleitet Wells Fargo Overweight
2024-09-06 Eingeleitet Stifel Buy
2024-02-23 Eingeleitet Cantor Fitzgerald Overweight
2023-09-22 Eingeleitet Wedbush Outperform
2023-03-23 Hochstufung H.C. Wainwright Neutral → Buy
2023-03-21 Hochstufung Guggenheim Neutral → Buy
2023-03-16 Hochstufung Oppenheimer Perform → Outperform
2022-07-18 Fortgesetzt Oppenheimer Perform
2022-04-04 Hochstufung Citigroup Neutral → Buy
2022-03-25 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-22 Herabstufung Citigroup Buy → Neutral
2022-03-22 Herabstufung Guggenheim Buy → Neutral
2022-03-22 Herabstufung Oppenheimer Outperform → Perform
2021-07-06 Hochstufung Citigroup Neutral → Buy
2021-01-25 Herabstufung Citigroup Buy → Neutral
2020-08-13 Eingeleitet Robert W. Baird Outperform
2020-08-06 Hochstufung Citigroup Neutral → Buy
2020-08-03 Eingeleitet H.C. Wainwright Buy
2020-05-19 Eingeleitet Citigroup Neutral
2020-05-19 Eingeleitet Guggenheim Buy
2020-05-19 Eingeleitet JP Morgan Overweight
2020-05-19 Eingeleitet Jefferies Buy
Alle ansehen

Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten

pulisher
06:35 AM

Alliancebernstein L.P. Trims Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

06:35 AM
pulisher
Apr 18, 2025

How the (ORIC) price action is used to our Advantage - news.stocktradersdaily.com

Apr 18, 2025
pulisher
Apr 16, 2025

Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo

Apr 16, 2025
pulisher
Apr 15, 2025

13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wellington Management Group LLP - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

Corebridge Financial Inc. Has $247,000 Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Makes New Investment in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by American Century Companies Inc. - Defense World

Apr 12, 2025
pulisher
Apr 07, 2025

ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN

Apr 07, 2025
pulisher
Apr 05, 2025

NEOS Investment Management LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat

Apr 05, 2025
pulisher
Apr 04, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

ORIC Strengthens Team with Strategic Equity Grants to Key New Hires - Stock Titan

Apr 04, 2025
pulisher
Apr 02, 2025

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - The AM Reporter

Apr 02, 2025
pulisher
Apr 01, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Consensus Target Price from Analysts - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan

Mar 25, 2025
pulisher
Mar 25, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance

Mar 24, 2025
pulisher
Mar 23, 2025

Wedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

Mar 23, 2025
pulisher
Mar 23, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

(ORIC) Investment Report - news.stocktradersdaily.com

Mar 22, 2025
pulisher
Mar 22, 2025

Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 21, 2025
pulisher
Mar 14, 2025

Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks

Mar 14, 2025
pulisher
Mar 12, 2025

(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Mar 12, 2025
pulisher
Mar 07, 2025

ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Mar 06, 2025
pulisher
Mar 06, 2025

ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat

Mar 06, 2025
pulisher
Mar 05, 2025

ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks

Mar 05, 2025
pulisher
Mar 04, 2025

Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat

Mar 04, 2025

Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):